Pomerantz LLP announces that a class action lawsuit has been filed
against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”)
BLCM, +0.74%
and certain of its officers. The class action, filed in
United States District Court, for the Southern District of Texas, and
docketed under 18-cv-00338, is on behalf of a class consisting of
investors who purchased or otherwise acquired Bellicum securities,
seeking to recover compensable damages caused by defendants’ violations
of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Bellicum securities between May
8, 2017, and January 30, 2018, both dates inclusive, you have until
April 9, 2018, to ask the Court to appoint you as Lead Plaintiff for the
class. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com
or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who
inquire by e-mail are encouraged to include their mailing address,
telephone number, and the number of shares purchased.
[Click
here to join this class action]
Bellicum operates as a clinical stage biopharmaceutical company. The
Company focuses on discovering and developing novel cellular
immunotherapies for various forms of cancer.
The Company’s lead clinical product candidate, BPX-501, is an adjunct
T-cell therapy administered after allogeneic hematopoietic stem cell
transplantation. Bellicum has represented that BPX-501 is currently
being evaluated in multiple Phase 1/2 clinical trials.
The Complaint alleges that throughout the Class Period, Defendants made
materially false and misleading statements regarding the Company’s
business, operational and compliance policies. Specifically, Defendants
made false and/or misleading statements and/or failed to disclose that:
(i) a substantial undisclosed risk of encephalopathy was associated with
the Company’s lead product candidate BPX-501; and (ii) as a result of
the foregoing, Bellicum’s public statements were materially false and
misleading at all relevant times.
On January 30, 2018, post-market, Bellicum issued a press release
entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501
Clinical Trials in the United States,” announcing that it had “received
notice from the U.S. Food and Drug Administration that U.S. studies of
BPX-501 have been placed on a clinical hold following three cases of
encephalopathy deemed as possibly related to BPX-501.”
On this news, Bellicum’s share price fell $2.12, or 25.85%, to close at
$6.08 on January 31, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and
Paris, is acknowledged as one of the premier firms in the areas of
corporate, securities, and antitrust class litigation. Founded by the
late Abraham L. Pomerantz, known as the dean of the class action bar,
the Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in the
tradition he established, fighting for the rights of the victims of
securities fraud, breaches of fiduciary duty, and corporate misconduct.
The Firm has recovered numerous multimillion-dollar damages awards on
behalf of class members. See www.pomerantzlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180311005023/en/
SOURCE: Pomerantz LLP
Pomerantz LLP
Robert S. Willoughby
rswilloughby@pomlaw.com
Copyright Business Wire 2018